FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
FDA grants orphan-drug designation for TauRx’s LMTX in frontotemporal dementia
ABERDEEN, Scotland and Singapore, 10th December, 2018 – TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to LMTX® for the
"treatment of frontotemporal dementia". The term Frontotemporal Dementia (FTD) covers a number of sub-types of dementia, all of which are characterized by a progressive loss of neurons in the frontal and/or temporal lobes of the brain.
Read more here.
FDA grants orphan-drug designation for LMTX
TauRx, a leader in neurodegenerative disease research, today announced that the US Food and Drug Administration (FDA) has granted orphan-drug designation for
Recent News
Marischal College, an iconic Aberdeen landmark, has been lit up purple to raise awareness of World Alzheimer’s Day.
Sep 21, 2021
Against the beautiful backdrop of the stormy sea and moody skies of Aberdeen, some of the TauRx team were fortunate to participate in Alzheimer Scotland’s Memory Walk, Sunday 19 September.
Sep 20, 2021
With a new case of dementia developing every three seconds, the importance of early diagnosis and intervention has never been clearer.
Sep 09, 2021
TauRx will be involved with raising awareness of Alzheimer Disease International's World Alzheimer's Month in September.
Sep 02, 2021